Search

Your search keyword '"A. Druzd-Sitek"' showing total 12 results
Start Over Author "A. Druzd-Sitek" Publisher elsevier bv
12 results on '"A. Druzd-Sitek"'

1. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial

Author

Dominik Dytfeld, Tomasz Wróbel, Krzysztof Jamroziak, Tadeusz Kubicki, Paweł Robak, Adam Walter-Croneck, Jarosław Czyż, Agata Tyczyńska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Adam Nowicki, Tomasz Szczepaniak, Anna Łojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Puła, Justyna Rybka, Maciej Majcherek, Lidia Usnarska-Zubkiewicz, Łukasz Szukalski, Agnieszka Końska, Jan Maciej Zaucha, Jan Walewski, Damian Mikulski, Olga Czabak, Tadeusz Robak, Oscar B Lahoud, Jeffrey A Zonder, Kent Griffith, Andrew Stefka, Ajay Major, Benjamin A Derman, and Andrzej J Jakubowiak

Subjects
Oncology
Published
2023

2. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial

Author

Dytfeld, Dominik, primary, Wróbel, Tomasz, additional, Jamroziak, Krzysztof, additional, Kubicki, Tadeusz, additional, Robak, Paweł, additional, Walter-Croneck, Adam, additional, Czyż, Jarosław, additional, Tyczyńska, Agata, additional, Druzd-Sitek, Agnieszka, additional, Giannopoulos, Krzysztof, additional, Nowicki, Adam, additional, Szczepaniak, Tomasz, additional, Łojko-Dankowska, Anna, additional, Matuszak, Magdalena, additional, Gil, Lidia, additional, Puła, Bartosz, additional, Rybka, Justyna, additional, Majcherek, Maciej, additional, Usnarska-Zubkiewicz, Lidia, additional, Szukalski, Łukasz, additional, Końska, Agnieszka, additional, Zaucha, Jan Maciej, additional, Walewski, Jan, additional, Mikulski, Damian, additional, Czabak, Olga, additional, Robak, Tadeusz, additional, Lahoud, Oscar B, additional, Zonder, Jeffrey A, additional, Griffith, Kent, additional, Stefka, Andrew, additional, Major, Ajay, additional, Derman, Benjamin A, additional, and Jakubowiak, Andrzej J, additional

Published
2023
Full Text
View/download PDF

3. OAB-010: Atlas: a phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma

Author

Jakubowiak, Andrzej, primary, Wrobel, Tomasz, additional, Jamroziak, Krzysztof, additional, Kubicki, Tadeusz, additional, Robak, Pawel, additional, Czyz, Jarosław, additional, Tyczynska, Agata, additional, Druzd-Sitek, Agnieszka, additional, Giannopoulos, Krzysztof, additional, Nowicki, Adam, additional, Lojko-Dankowska, Anna, additional, Matuszak, Magdalena, additional, Gil, Lidia, additional, Pula, Bartosz, additional, Rybka, Justyna, additional, Usnarska-Zubkiewicz, Lidia, additional, Czabak, Olga, additional, Stefka, Andrew, additional, Derman, Benjamin, additional, and Dytfeld, Dominik, additional

Published
2022
Full Text
View/download PDF

4. OAB-010: Atlas: a phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma

Author

Andrzej Jakubowiak, Tomasz Wrobel, Krzysztof Jamroziak, Tadeusz Kubicki, Pawel Robak, Jarosław Czyz, Agata Tyczynska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Adam Nowicki, Anna Lojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Pula, Justyna Rybka, Lidia Usnarska-Zubkiewicz, Olga Czabak, Andrew Stefka, Benjamin Derman, and Dominik Dytfeld

Subjects
Cancer Research, Oncology, Hematology
Published
2022

5. Procollagen I amino-terminal propeptide as a potential marker for multiple myeloma

Author

Magdalena Chechlinska, Maria Kowalska, Janina Kaminska, Agnieszka Druzd-Sitek, Malgorzata Fuksiewicz, Beata Kotowicz, Jan Walewski, and Małgorzata Syczewska

Subjects
Adult, Male, medicine.medical_specialty, Bone disease, Osteocalcin, Clinical Biochemistry, Sensitivity and Specificity, Collagen Type I, Bone remodeling, chemistry.chemical_compound, Sex Factors, Internal medicine, Immunopathology, Biomarkers, Tumor, medicine, Humans, Bone Resorption, Multiple myeloma, Aged, Aged, 80 and over, biology, business.industry, Age Factors, Albumin, General Medicine, Middle Aged, Prognosis, medicine.disease, Survival Analysis, Peptide Fragments, Vascular endothelial growth factor, Procollagen peptidase, Endocrinology, chemistry, biology.protein, Female, Multiple Myeloma, Peptides, business, Procollagen, Follow-Up Studies
Abstract

Objectives Investigating relationship between bone markers, cytokines and conventional prognostic parameters in patients with multiple myeloma (MM) and to assess the clinical application of bone turnover markers. Design and methods Sixty-four patients with MM were examined before treatment and followed for survival for over 7 years. Serum concentrations of bone markers and cytokines were determined by the Roche and R&D kits, respectively. Standard deviation scores (SDS) were employed to normalize values. Results Collagen fragments (β-CTX) were elevated in 47%, procollagen I amino-terminal propeptide (PINP)—in 28%, and osteocalcin (OC) in 11% of patients. The values of the SDS of PINP and OC, but not β-CTX significantly decreased with MM stage. β-CTX inversely correlated with vascular endothelial growth factor (VEGF) and albumin, and directly correlated with serum macrophage colony-stimulating factor (M-CSF). OC values correlated with albumin and β2-microglobulin. PINP inversely correlated with LDH. The SDS values of PINP were significantly lower in MM patients with advanced bone disease. Conclusions Circulating PINP concentration may be a useful marker for monitoring of treatment of multiple myeloma patients with bone lytic lesions, in particular, of patients treated with preoteasome inhibitors.

Published
2010

7. Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients—Report of the Polish Myeloma Group

Author

Usnarska-Zubkiewicz, L., primary, Dębski, J., additional, Butrym, A., additional, Legieć, W., additional, Hus, M., additional, Dmoszyńska, A., additional, Stella-Hołowiecka, B., additional, Zaucha, J.M., additional, Januszczyk, J., additional, Rymko, M., additional, Torosian, T., additional, Charliński, G., additional, Lech-Marańda, E., additional, Malenda, A., additional, Jurczyszyn, A., additional, Urbańska-Ryś, H., additional, Druzd-Sitek, A., additional, Błońska, D., additional, Urbanowicz, A., additional, Hołojda, J., additional, Pogrzeba, J., additional, Rzepecki, P., additional, Hałka, J., additional, Subocz, E., additional, Becht, R., additional, Zdziarska, B., additional, Dytfeld, D., additional, Nowicki, A., additional, Bołkun, Ł., additional, Kłoczko, J., additional, Knopińska-Posłuszny, W., additional, Zubkiewicz-Kucharska, A., additional, and Kuliczkowski, K., additional

Published
2016
Full Text
View/download PDF

8. Skin Involvement by Multiple Myeloma: a Multi-Institutional Retrospective Study of 53 Patients

Author

Jorge J. Castillo, K. Gawro ski, Edvan de Queiroz Crusoe, Agnieszka Druzd-Sitek, Sonja Zweegman, Dorotea Fantl, Xavier Leleu, David H. Vesole, Jan Walewski, Suzanne Lentzsch, Leo Rasche, Julio Dávila, Magdalena Olszewska-Szopa, Ajay K. Nooka, Giuseppe Mele, Tomas Pika, Kristian Thidemann Andersen, Aleksander B. Skotnicki, Morie A. Gertz, Michel Delforge, A.C. Monteiro de Castro, Artur Jurczyszyn, Alessandro Gozzetti, Massimo Gentile, V. Hungria, Vladimir Maisnar, Jo Caers, Andrew Yee, Chaim Shustik, Hematology, CCA - Disease profiling, CCA - Innovative therapy, and CCA - Quality of life

Subjects
Cancer Research, medicine.medical_specialty, Oncology, business.industry, Prior Radiotherapy, Internal medicine, medicine, Retrospective cohort study, Hematology, business, medicine.disease, Gastroenterology, Multiple myeloma
Abstract

G-alone G-cyclo P-value No. of patients 112 (81%) 26 (19%) Median age (years; range) 61 (36-72) 55 (35-65) Male/female 65(58%)/47(42%) 17(65%)/9(35%) P1⁄40.47 Prior radiotherapy exposure 17 (15%) 5 (19%) P1⁄40.61 Median no. of bortezomib doses 16 (11-24) 16 (15-20) Median cumulative bortezomib dose (mg/m) 20.8 (14.3 e 31.2) 20.8 (16.0-22.1) Cyclophosphamide mobilisation dose 1.5 g/m NA 7 (24%) 2 g/m NA 19 (76%) G-CSF dose for mobilisation 5mg/kg daily 0 7 (27%) 10mg/kg daily 96 (86%) 18 (69%) 10mg/kg twice daily 16 (14%) 0 NA 0 1 (4%) PB CD34+ day of planned collection (10/L; median; range) 52 (8-326) 69 (0-227) P1⁄40.87 >100 26 (23%) 8 (31%) >50-100 31 (28%) 7 (27%) 20-50 39 (35%) 8 (31%) 4-6 49 (44%) 11 (44%) >6 44 (40%) 12 (48%) Median CD34+ yield in radiotherapy patients (10/kg; range) 5.8 (2.2-17.3) 4.5 (3.8-6.9) Outcomes of collection Success without intervention 38 (34%) 13 (50%) P1⁄40.49 Success with extra days of G-CSF 62 (55%) 11 (42%) Success with plerixafor rescue 7 (6%) 1 (4%) Failed first collection; no other attempts 1 (1%) 0 Failed first collection with subsequent successful collection 3 (3%) 1 (4%) Target yield not reached but deemed sufficient 1 (1%) 0

Published
2015

9. Outcome of primary gastrointestinal compared to nodal diffuse large B cell lymphoma in a series of consecutive patients treated at a single institution

Author

Joanna Romejko-Jarosinska, M. Szyman´ski, A. Druzd-Sitek, Michal Osowiecki, L. Targonski, E. Paszkiewicz-Kozik, Jan Walewski, and K. Martyna

Subjects
medicine.medical_specialty, Series (stratigraphy), business.industry, Hematology, medicine.disease, Outcome (game theory), Oncology, Immunology, Medicine, Radiology, Single institution, business, NODAL, Diffuse large B-cell lymphoma
Published
2016

10. Skin Involvement by Multiple Myeloma: a Multi-Institutional Retrospective Study of 53 Patients

Author

Jurczyszyn, A., primary, Hungria, V., additional, Crusoe, E., additional, Monteiro de Castro, A.C., additional, Pika, T., additional, Delforge, M., additional, Leleu, X., additional, Rasche, L., additional, Nooka, A.K., additional, Druzd-Sitek, A., additional, Walewski, J., additional, Davila, J., additional, Caers, J., additional, Maisnar, V., additional, Gertz, M., additional, Gentile, M., additional, Fantl, D., additional, Mele, G., additional, Vesole, D.H., additional, Olszewska-Szopa, M., additional, Yee, A.J., additional, Shustik, C., additional, Lentzsch, S., additional, Andersen, K.T., additional, Zweegman, S., additional, Gawro ski, K., additional, Gozzetti, A., additional, Skotnicki, A.B., additional, and Castillo, J.J., additional

Published
2015
Full Text
View/download PDF

11. Central Nervous System Involvement by Multiple Myeloma: a Multi-Institutional Retrospective Study of 172 Patients

Author

Jurczyszyn, A., primary, Gozzetti, A., additional, Cerase, A., additional, Hungria, V., additional, Crusoe, E., additional, Silva, A.L., additional, Vij, R., additional, Fiala, M.A., additional, Caers, J., additional, Rasche, L., additional, Nooka, A.K., additional, Lonial, S., additional, Vesole, D.H., additional, Philip, S., additional, Gangatharan, S., additional, Druzd-Sitek, A., additional, Walewski, J., additional, Corso, A., additional, Cocito, F., additional, Vekemans, M.-C.M., additional, Atilla, E., additional, Beksac, M., additional, Leleu, X., additional, Davila, J., additional, Badros, A., additional, Niesvizky, R., additional, Aneja, E., additional, Abildgaard, N., additional, Kastritis, E., additional, Fantl, D., additional, Schutz, N., additional, Pika, T., additional, Olszewska-Szopa, M., additional, Butrym, A., additional, Usnarska-Zubkiewicz, L., additional, Grz ko, N., additional, Usmani, S., additional, Nahi, H., additional, Chim, C.S., additional, Shustik, C., additional, dry, K.M., additional, Lentzsch, S., additional, widerska, A., additional, Helbig, G., additional, Guzicka-Kazimierczak, R., additional, Lendvain, N., additional, Waage, A., additional, Andersen, K.T., additional, Murakami, H., additional, Zweegman, S., additional, Skotnicki, A.B., additional, and Castillo, J.J., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results